Sanofi Enter into Agreement with RadioMedix and Orano Med for Next-Generation Radioligand Therapy to Treat Rare Cancers
Friday, September 13, 2024
Sanofi has entered into an exclusive licensing agreement with RadioMedix, and Orano Med, a French biotechnology subsidiary of Orano Group, to advance the development of AlphaMedix™.
As part of the agreement, Sanofi will take responsibility for the global commercialisation of AlphaMedix™, while Orano Med will oversee its manufacturing through a global industrial platform currently in development. RadioMedix and Orano Med will receive an upfront payment of €100 million and may earn up to €220 million in sales milestones, along with tiered royalties. The deal is subject to standard regulatory approvals.
This collaboration is part of Sanofi's broader strategy to advance innovative treatments for difficult-to-treat cancers, leveraging its expertise in immunoscience and oncology.
AlphaMedix™ utilises a peptide complex radiolabelled with lead-212 (212Pb), an alpha particle generator, to target somatostatin receptors. The therapy is currently in late-stage clinical development, with promising results from early trials indicating its potential in cancer treatment.
The US Food and Drug Administration (FDA) has granted AlphaMedix™ Breakthrough Therapy Designation for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in patients who have not previously received peptide-receptor radionuclide therapy. Clinical studies have shown that the treatment is well tolerated, with an overall response rate (ORR) of 62.5%.
Neuroendocrine tumours (NETs) are a rare and heterogeneous group of cancers that most commonly occur in the gastrointestinal tract and pancreas, although they can also affect other tissues. Approximately 12,000 people in the United States are diagnosed with NETs annually, with a five-year survival rate of 60% in cases where the disease has metastasised.
Despite being rare, the global prevalence of NETs is increasing, affecting about 35 in every 100,000 people worldwide.
This next-generation radioligand therapy (RLT) is aimed at treating rare cancers, specifically targeting somatostatin-receptor expressing neuroendocrine tumours (NETs), which are typically unresectable or metastatic.
Source: sanofi.com
